The Use of GM-CSF and G-CSF in the Treatment of Acute Leukemias

References

• Estey E. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994; 83: 2015–19
   PubMed Web of Science ®Google Scholar
• Touw Groot-Loonen I., Broeders L., et al. Recombinant hematopoietic growth factors fail to induce a proliferative response in precursor B acute lymphoblastic leukemia. Leukemia 1989; 3: 356–63
   PubMed Web of Science ®Google Scholar
• Makrynikola V., Kabral A., Bradstock K.F. Effects of recombinant human cytokines in precursor-B acute lymphoblastic leukemia cells. Exp. Hematol. 1991; 19: 674–79
   PubMed Web of Science ®Google Scholar
• Ode D.L., Zhou M., Findley H.W., Abdel-Mageed A., Ragab A.H. The effect of recombinant GM-CSF and G-CSF on the bone marrow cells of children with acute lymphoblastic leukemia. Leukemia 1992; 6: 1210–12
   PubMed Web of Science ®Google Scholar
• Freedman M.H., Grunberger T., Correa P., Axelrad A.A., Dube I.D., Cohen A. Autocrine and paracrine growth control by granulocyte-monocyte colony-stimulating factor of acute lymphoblastic leukemia cell. Blood 1993; 81: 3068–75
   PubMed Web of Science ®Google Scholar
• Mirro J., Hurwitz C.A., Behm F.G., et al. Effects of recombinant human hematopoietic growth factors on leukemic blasts from children with acute myeloblastic or lymphoblastic leukemia. Leukemia 1993; 7: 1026–33
   PubMed Web of Science ®Google Scholar
• Tsuchiya H., Adachi N., Asou N., et al. Responses to granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage CSF in phl-positive acute lymphoblastic leukemia with myeloid surface markers. Blood 1991; 77: 411–3
   PubMed Web of Science ®Google Scholar
• Komada Y., Zhou Y.W., Zhang S.L., Azuma E., Sakurai M. Role in growth regulation of cytokines and cytokine receptors in acute lymphoblastic leukemia expressing myeloid markers. Br. J. Haematol. 1992; 84: 408–15
   Web of Science ®Google Scholar
• Shimoda K., Okamura S., Harada N., et al. Granulocyte colony-stimulating factor receptors on human acute leukemia: Biphenotype leukemic cells possess granulocyte colony-stimulating factor receptors. Cancer Research 1992; 52: 3052–55
   PubMed Web of Science ®Google Scholar
• Tsao C.J., Cheng T.Y., Chang S.L., Su W.J., Tseng J.Y. Effects of granulocyte-macrophage colony stimulating factor and interleukin-6 on the growth of leukemic blasts in suspension culture. Int. J. Cell. Cloning 1992; 10: 166–72
   PubMedGoogle Scholar
• Brandt S.J., Peters W.P., Arwater S.K., et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 1988; 318: 869–76
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., Singer J.W., Buckner C.D., et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834–6
   PubMed Web of Science ®Google Scholar
• Blazar S.R., Kersey J.H., McGlave P.B., et al. In vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989; 73: 849–57
   PubMed Web of Science ®Google Scholar
• Powles R., Smith C., Milan S., et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417–20
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., Buckner C.D., Appelbaum F.R., et al. Phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 1991; 77: 2065–71
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C., Mangoni L., Almici C., et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in pateints with lymphoid malignancies transplanted with unpurged or adjusted dose Mafosfamide-purged autologous marrow. Blood 1992; 80: 2412–18
   PubMed Web of Science ®Google Scholar
• Nemunaitis J., Rabinowe S.N., Singer J.W., et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl. J. Med. 1991; 324: 1773–78
   PubMed Web of Science ®Google Scholar
• DeWitte T., Gratwohl A., Van der Lely N., et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 1992; 79: 1359–65
   PubMed Web of Science ®Google Scholar
• Link H., Boogaerts M.A., Carella A.M., et al. A controlled trial of recombinant granulocyte-macrophage colony-stimulating factor after total body irradiation. high-dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992; 80: 2188–95
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Prentice H.G., Bacigalupo A., et al. A phase III randomized placebo controlled study of lenograstim (glycosylated rHu G-CSF) in pediatric and adult autologous or allogeneic bone marrow transplantation. Lancet 1994; 843: 696–700
   Web of Science ®Google Scholar
• Rabinowe S.N., Neuberg D., Bierman P.J., et al. Long term follow-up of a Phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993; 131: 1903–08
   Google Scholar
• Ohno R., Tomonaga M., Kobayashi T., et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N. Engl. J. Med. 1990; 523: 871–7
   Web of Science ®Google Scholar
• Kantarjian H., Estey E., O'Brien S., et al. Intensive chemotherapy with mitoxantrone and high dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of acute lymphocytic leukemia. Blood 1992; 79: 876–81
   PubMed Web of Science ®Google Scholar
• Ohno R., Tomonaga M., Ohshima T., et al. A randomized controlled study of granulocyte colony-stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Int. J. Hematol. 1993; 58: 73–81
   PubMed Web of Science ®Google Scholar
• Larson R.A., Linker C.A., Dodge R.K., et al. Granulocyte colony-stimulating factor (filgrastim) reduces the time to neutrophil recovery in adults with acute lymphoblastic leukemias receiving intensive remission induction chemotherapy: Cancer and Leukemia Group B study 911. Proceed ASCO 1994; 13: 305, Abstract 995
   Google Scholar
• Ottman O.G., Hoelzer D., Gracien E., et al. Concomitant r-met Hu G-CSF (Filgrastim) and intensive chemoradiotherapy as induction treatment in adult ALL. Blood 1993; 193a, Suppl 1 Abstr, act 757
   Google Scholar
• Weiss M., Berman E., Maslak P., et al. Rapid remission induction therapy in adult acute lymphoblastic leukemia without vincristine or prednisone. Blood 1993; 56a, Suppl 1 Abstract 212
   Google Scholar
• Wu D., Harousseau J.L., Ifrah N., et al. A randomized placebo controlled study of GM-CSF given after AML like intensive therapy in adult acute lymphoblastic leukemia. 1994, Submitted for publication
   Google Scholar
• Welte K., Mempel K., Reiter A., et al. A randomized Phase HI study of recombinant human granulocyte colony-stimulating factor in childhood high risk acute lymphoblastic leukemia. Blood 1993; 194a, Suppl 1 Abstract 761
   Google Scholar
• Lange B., Valtieri M., Santoli D., et al. Growth factor requirement of childhood acute leukemia: establishment of GM-CSF dependent cell lines. Blood 1987; 70: 192–99
   PubMed Web of Science ®Google Scholar
• Vellenga E., Ostapovicz D.O, Roorke B., et al. Effects of 1L3, GM-CSF and G-CSF on proliferation of leukemic clonogeinic cells in short-term and long-term cultures. Leukemia 1987; 1: 584–89
   PubMed Web of Science ®Google Scholar
• Griffin J.D., Young D., Hemnann F., Wiper D., Wagner K., Sabbath K.D. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986; 67: 1448–53
   PubMed Web of Science ®Google Scholar
• Asano Y., Shiboya T., Okamura S., et al. Effect of recombinant granulocyte-macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogeinic leukemic blast cells. Cancer Res. 1987; 47: 5647–48
   PubMed Web of Science ®Google Scholar
• Kelleher C., Miyauchi J., Wong G., Clark S., Minden M., McCulloch E.A. Synergism between recombinant growth factors, GM-CSF and G-CSF, acting on the blast cells of acute myeloblastic leukemia. Blood 1987; 69: 149
   Google Scholar
• Vellenga E., Young D.C., Wagner K., Wiper D., Ostapovicz D., Griffin J.D. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987; 69: 1771–76
   PubMed Web of Science ®Google Scholar
• Vellenga E., Delwel R., Touw I., Lowenberg B. Patterns of acute myeloid leukemic colony growth in response to recombinant granulocyte-macrophage colony stimulating factor. Exp. Hematol. 1987; 15: 652–
   PubMed Web of Science ®Google Scholar
• Delwel R., Salem M., Pellens C., et al. Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic growth factors in a serum-free culture system. Blood 1988; 72: 1944–49
   PubMed Web of Science ®Google Scholar
• Hoang T., Nara N., Wong G., Clark S., Minden M.D., McCulloch E.A. Effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukemia. Blood 1988; 68: 313–16
   Web of Science ®Google Scholar
• Lista P., Elrizzi M.F., Avanzi G. Induction of proliferation of myeloblastic leukemia. cells with hematopoietic growth factors. Leukemia Res. 1988; 12: 441–47
   PubMed Web of Science ®Google Scholar
• Budel L.M., Touw I.R., Delwel R., Lowenberg B. Granulocyte colony-stimulating factor receptors in human acute myelocytic leukemia. Blood 1989; 74: 2668–73
   PubMed Web of Science ®Google Scholar
• Onetto-Pothier N., Aumoni N., Haman A., et al. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood 1990; 75: 59–66
   PubMed Web of Science ®Google Scholar
• Estey E.H., Dixon D., Kantarjian H., et al. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990; 75: 1766–69
   PubMed Web of Science ®Google Scholar
• Buchner T., Hiddemann W., Koenigsmann M., et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute: myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190–97
   PubMed Web of Science ®Google Scholar
• Kantarjian H., Talpaz M., Kontoyiannis D., et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicine, high-dose cytarabine and granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 1992; 10: 398–405
   PubMed Web of Science ®Google Scholar
• Rowe J.M., Andersen J., Mazza J.J., et al. Phase III randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor (GM-CSF) in adult patients (55–70 years) with acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Croup (ECOG). Blood 1993; 329a, 82 Suppl 1 Abstract n° 1299
   Google Scholar
• Stone R., George S., Berg G, Paciucci P., Schiffer C. GM-CSF versus placebo during remission induction for patients ≥60 years old with de novo acute myeloid leukemia. Proceed. ASCO 1994; 13: 354, Abstract 992
   Google Scholar
• Dombret H., Personal communication
   Google Scholar
• Souza L.M., Boone T.C., Abrilove J.L., et al. Recombinant human granulocyte colony-stimulating factor: Effets on normal and leukemic myeloid cells. Science 1986; 232: 61–5
   PubMed Web of Science ®Google Scholar
• Begley C.G., Metcalf D., Nicola N.A. Purified colony-stimulating factors (G-CSF and GM-CSF) induce differenciation in HL-60 cells with suppression of clonogenicity. Int. J. Cancer 1987; 39: 99–105
   PubMed Web of Science ®Google Scholar
• Giralt S., Escudier S., Kantarjian M., et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogenic bone marrow transplantation. N. Engl. J. Med. 1993; 329: 757–81
   PubMed Web of Science ®Google Scholar
• Ohno R., Hiraoka A., Tanimoto M., et al. No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemias who received granulocyte colony-stimulating factor for life threatening infection during remission induction and consolidation therapy. Blood 1993; 81: 561
   PubMed Web of Science ®Google Scholar
• Tafuri A., Andreeff M. Kinetic rationale forcytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4: 8216–34
   Google Scholar
• Miyauchi J., Kelleher C.A., Wang C., et al. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989; 73: 1272–8
   PubMed Web of Science ®Google Scholar
• Cannistra S.A., Groshek P., Griffin J.D. Granulocyte-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3: 328–44
   PubMed Web of Science ®Google Scholar
• Lista P., Brizi M., Rossi M., et al. Different sensitivity of normal and leukaemic progenitor cells to Ara-C and IL-3 combined treatment. Br. J. Haematol. 1990; 73: 21–6
   Web of Science ®Google Scholar
• Rutturini A., Santucci A.M., Gale R.D., et al. GM-CSF incubation prior to treatment with cytarabine or doxorubicine enhances drug activity against AML cells in vitro: A model for leukemia chemotherapy. Leuk. Res. 1990; 9: 743–9
   Web of Science ®Google Scholar
• Karp J.E., Burke P.J., Donehower R.P. Effect of rh GM-CSFon intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: Comparability with drug-induced humoral stimulatory activity. Leukemia 1990; 4: 553–
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Kielhl M., Zuhlsdorf M., et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Semin. Oncol. 1992; 19: 31–7, Suppl 21
   PubMed Web of Science ®Google Scholar
• Yang G.S., Minden M.D., McCulloch E.A. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia 1993; 7: 1012–9
   PubMed Web of Science ®Google Scholar
• Bhalla K., Birkhofer M., Arlin Z., et al. Effect of recombinant GM-CSF on the metabolism of cytosine-arabinoside in normal and leukemic human bone marrow cells. Leukemia 1988; 2: 810–3
   PubMed Web of Science ®Google Scholar
• Van der Lely N., DeWitte T., Mous P. Prolonged exposure to cytosine arabinoside in the presence of haematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp. Hematol. 1991; 19: 267–72
   PubMed Web of Science ®Google Scholar
• Koistinen P., Wang C., Curtis J.E., et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 1991; 5: 789–95
   PubMed Web of Science ®Google Scholar
• Lotem J., Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor p I and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750–7
   PubMed Web of Science ®Google Scholar
• Bettelheim P., Valent P., Andreeff M., et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in denovo acute myeloid leukemia. Blood 1991; 77: 700–11
   PubMed Web of Science ®Google Scholar
• Estey E., Thall P.F., Kantarjian H., et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood, 79: 2246–55
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Fenaux P., Reiffers J., et al. Granulocyte-macrophage colony stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993; 7: 372–7
   PubMed Web of Science ®Google Scholar
• Ohno R., Naoe T., Kanamaro A., et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994; 73: 2086–92
   Google Scholar
• Estey Thall E.P., Andreeff M., et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol. 1994; 12: 671–8
   PubMed Web of Science ®Google Scholar
• Harousseau J.L., Witz F., Cahn J.Y., et al. GM-CSF during and after induction treatment for acute myeloid leukemia (AML) in elderly patients. 1994, First Meeting EHA Brussels, Abstract
   Google Scholar
• Buchner T., Hiddemann W., Rottmann R., et al. Multiple course chemotherapy with or without GM-CSF priming and long-term administration for newly dagnosed AML. Proceed. Am. Soc. Clin. Oncol. 1993; 12: 301, Abstract 985
   Google Scholar